Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis

Abstract Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, with MYD88 mutations associated with poor outcomes. Enhancing standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy with targeted agents such as zanubrutinib, a selective Bruton t...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Cancer Immunology, Immunotherapy
المؤلفون الرئيسيون:	Xiubin Xiao, Shunzong Yuan, Xilin Chen, Xia Liu, Ruiqing Zhao, Shihua Zhao, Yun Lu, Yi Ma, Junli Chen, Yueqi Wang, Nana Cheng, Hua Yin, Honghao Gao, Pan Feng, Wenrong Huang
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Springer 2025-07-01
الموضوعات:	Zanubrutinib R-CHOP regimen MYD88 Diffuse large B-cell lymphoma Propensity score-matched analysis
الوصول للمادة أونلاين:	https://doi.org/10.1007/s00262-025-04090-4